MCL1 and neoplasm: In addition, we found that S63845/venetoclax combination exhibited marked anti-tumor activity in the U266 xenograft model resistant to both inhibitors, in agreement with studies that report efficacy of venetoclax with MCL1 inhibitors in myeloma models19,20.